Edition:
United Kingdom

Shire PLC (SHP.L)

SHP.L on London Stock Exchange

3,760.50GBp
12 Dec 2017
Change (% chg)

-- (--)
Prev Close
3,760.50
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
2,802,429
52-wk High
5,067.00
52-wk Low
3,435.50

Summary

Name Age Since Current Position

Susan Kilsby

58 2014 Independent Non-Executive Chairman of the Board

Flemming Ornskov

59 2013 Chief Executive Officer, Executive Director

Joanne Cordeiro

2017 Chief Human Resource Officer

Howard Mayer

Senior Vice President -Head of Research and Development

Gisele Dion

51 2017 Chief Accounting Officer, Corporate Controller

William Mordan

47 2015 General Counsel, Company Secretary

Perry Sternberg

48 2016 Head - U.S. Commercial

Kim Stratton

54 2016 Head - International Commercial

Philip Vickers

56 2014 Head - Research and Development

Matthew Walker

53 2016 Head - Technical Operations

Olivier Bohuon

58 2015 Non-Executive Director

Ian Clark

56 2017 Non-Executive Director

Gail Fosler

69 2016 Non-Executive Director

Sara Mathew

62 2015 Non-Executive Director

Albert Stroucken

69 2016 Non-Executive Director

Dominic Blakemore

47 2014 Non-Executive Independent Director

William Burns

69 2016 Senior Non-Executive Independent Director

Steven Gillis

63 2012 Non-Executive Independent Director

David Ginsburg

64 2010 Non-Executive Independent Director

Anne Minto

63 2010 Non-Executive Independent Director

Ian Karp

2016 Head of Investor Relations

Biographies

Name Description

Susan Kilsby

Ms. Susan Saltzbart Kilsby serves as Independent Non-Executive Chairman of the Board of Shire Plc. Susan served as an independent Non-Executive Director prior to her appointment as Chairman on April 29, 2014. Susan brings to her role extensive M&A and finance experience having enjoyed a distinguished global career in investment banking. She held senior positions with The First Boston Corporation, Bankers Trust, Barclays de Zoete Wedd and most recently Credit Suisse where she was Chairman of the EMEA Mergers & Acquisitions team until 2009 and a part-time senior advisor until 2014. Susan is also a former Director of Keurig Green Mountain, Inc., L’Occitane International S.A. and Coca-Cola HBC AG. She holds a BA in Economics and a MBA. She is with BBA Aviation plc (Non- Executive Director), Goldman Sachs International (Non-Executive Director) and Fortune Brands Home & Security, Inc. (Non-Executive Director).

Flemming Ornskov

Dr. Flemming Ornskov, M.D., MBA, MPH, serves as Chief Executive Officer, Executive Director of Shire Plc., effective April 30, 2013. Flemming brings to his role his operational and medical knowledge and his extensive international, strategic and operational experience in the pharmaceutical sector. He formerly held the position of Non-Executive Chairman of Evotec AG and was Non-Executive Director of PCI Biotech Holding ASA. From 2010 to 2012 he was Chief Marketing Officer and Global Head, Strategic Marketing for General and Speciality Medicine at Bayer. From 2008 to 2010 Flemming served as Global President, Pharmaceuticals and OTC at Bausch & Lomb, Inc. He also served as Chairman, and later as President and Chief Executive Officer, of Life-Cycle Pharma A/S from 2006 to 2008, and as President and Chief Executive Officer of Ikaria, Inc. from 2005 to 2006. Earlier in his pharmaceutical career Flemming held roles of increasing responsibility at Merck & Co., Inc. and Novartis AG, following a distinguished period spent in hospitals and academic medicine. Flemming received his MD from the University of Copenhagen, MBA from INSEAD and Master of Public Health from Harvard University.

Joanne Cordeiro

Ms. Joanne Cordeiro is Chief Human Resource Officer of the Company. Joanne joined Shire in March 2011 and has been serving as Interim Head of Human Resources since March 2017. Before joining Shire, Joanne served in various Human Resources management and executive search roles at Teradyne Inc., Covansys Corporation (now a DXC Technology Company), Avid Technology, Inc., and Sybase Inc.

Howard Mayer

Dr. Howard Mayer, M.D., has been appointed as Chief Medical Officer of the Company, with effective from January 2018. Howard Mayer, MD, is currently Senior Vice President and Head of R&D (ad interim) at Shire. Previously, he was Senior Vice President and Head of Global Clinical Development at the Company. Dr. Mayer joined Shire in 2012 and has been responsible for global clinical development across immunology, hereditary angioedema, hematology, lysosomal storage disorders, gastrointestinal / internal medicine / endocrine, ophthalmics, a growing franchise in oncology, and neuroscience. Prior to joining Shire, he served as Chief Medical Officer at EMD Serono, a division of Merck KGaA. Dr. Mayer obtained his BA from the University of Pennsylvania and his MD from Albert Einstein College of Medicine in New York, which was followed by an internship and residency at Mount Sinai Hospital and an Infectious Diseases fellowship at Harvard Medical School. He currently serves on the Board of Directors for Genocea Biosciences, as well as the scientific advisory boards of Macrolide Pharmaceuticals and Arsanis Biosciences.

Gisele Dion

Ms. Gisele Dion serves as Chief Accounting Officer, Corporate Controller of the Company. Ms. Dion has served as Shire’s Corporate Controller since January 19, 2016. Before joining Shire in 2016, Ms. Dion served as Corporate Controller of Biogen since December 2013 and as Senior Director, Finance at Biogen from February 2011.

William Mordan

Mr. William Mordan serves as General Counsel, Company Secretary of the Company. Bill joined Shire in 2015 and serves as General Counsel and Company Secretary. He previously served as General Counsel and Company Secretary at Reckitt Benckiser Group plc in the UK, prior to which he held various roles at Procter & Gamble in the U.S., Mexico and Brazil. Earlier in his career, Bill served as a clerk in the U.S. Court of Appeals for the Sixth Circuit. He holds a Juris Doctor degree from the University of North Carolina.

Perry Sternberg

Mr. Perry Sternberg serves as Head - U.S. Commercial of the Company. Perry joined Shire in 2013 and is Head of U.S. Commercial. He was previously Vice President & General Manager, U.S. & Canada Pharmaceuticals at Bausch & Lomb. Prior to that, Perry held various roles at Novartis Ophthalmics, Novartis Pharmaceuticals and Merck & Co., Inc. He holds a Bachelor’s degree in Animal Bioscience from Pennsylvania State University.

Kim Stratton

Ms. Kim Stratton serves as Head - International Commercial of the Company. Kim joined Shire in 2013 and is Head of International Commercial. She was previously Global Head of Group Country Management & External Affairs for Novartis. Prior to that, Kim held various roles of increasing responsibility at Novartis, Bristol Myers Squibb and AstraZeneca. She qualified as a State Registered Nurse at the Royal North Shore Hospital.

Philip Vickers

Mr. Philip J. Vickers is Head - Research and Development of the Company. Philip joined Shire in 2010 and is Head of Research and Development. He previously led Research and Development for Shire’s Rare Diseases Business Unit, prior to which he held various roles at Resolvyx Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Pfizer and Merck & Co. He holds a PhD in Biochemistry from the University of Toronto.

Matthew Walker

Mr. Matthew Walker, BSCHE serves as Head - Technical Operations of the Company. Matt joined Shire in 2016 and is Head of Technical Operations. Previously he worked at Pfizer for over 20 years in engineering and operations roles within the supply organization — his last two positions being Operations Lead for Sterile Injectables and Operations Lead for Biologics/Vaccines. Prior to Pfizer, Matt worked as a Project Director for John Brown Engineering and Construction. He holds a Bachelor’s degree in Chemical Engineering from Tufts University.

Olivier Bohuon

Mr. Olivier Bohuon is Non-Executive Director of the Company. Olivier brings to the Board his extensive international business and leadership experience gained through roles held in pharmaceutical and healthcare companies across Europe, the Middle East and the U.S. He currently holds the position of Chief Executive Officer at Smith & Nephew plc, having previously served as Chief Executive Officer and President of Pierre Fabre Group and as President of Abbott Pharmaceuticals; a division of U.S.-based Abbott Laboratories. Olivier also held diverse commercial leadership positions at GlaxoSmithKline and its predecessor companies in France. He has an MBA from HEC Paris School of Management and a doctorate in Pharmacy from the University of Paris. Key appointments are Smith & Nephew plc (Chief Executive Officer), Biotech Promise (Non-Executive Director) and Virbac SA (Non-Executive Director).

Ian Clark

Mr. Ian T. Clark is the Non-Executive Director of the Company. Mr. Ian brings to the Board his extensive leadership and biotechnology sector experience. Ian served as Chief Executive Officer and Director of Genentech Inc. (part of the Roche Group) and Head of North American Commercial Operations for Roche until 2016. From 2003 to 2010 he held the positions of Head of Global Product Strategy and Chief Marketing Officer, Executive Vice President — Commercial Operations and Senior Vice President and General Manager — BioOncology at Genentech. Prior to this Ian was appointed President of Novartis Canada, having previously served as Chief Operating Officer for Novartis United Kingdom. He also held various sales and marketing roles at Sanofi and Ivax. Ian holds a Bachelor’s degree in Biological Sciences from the University of Southampton. Key appointments are TerraVia Holdings Inc. (Non-Executive Director), Agios Pharmaceuticals, Inc. (Non-Executive Director), Corvus Pharmaceuticals, Inc. (Non-Executive Director), Kite Pharma, Inc. (Non-Executive Director) and Gladstone Institute (Member).

Gail Fosler

Ms. Gail D. Fosler is Non-Executive Director of the company. Gail brings to the Board her commercial, public policy and economics experience. She is President of The GailFosler Group LLC, a strategic advisory service for global business leaders and public policy makers, which she has led since 2010. Prior to this, Gail spent over 20 years at The Conference Board where she served as President and Trustee, Executive Vice President and Chief Economist. Gail is a former Director of Baxter International, Inc., Baxalta, Inc., Swiss Reinsurance America Corporation and Caterpillar, Inc. She holds a Master of Business Administration degree in Finance from New York University and a Bachelor of Arts Degree in Economics from the University of Southern California. Key appointments are The GailFosler Group LLC (President) and Deschner Corporation (Non- Executive Director and Chair).

Sara Mathew

Ms. Sara Mathew is Non-Executive Director of the Company. Sara brings to the Board her financial, strategic and technological experience having held various corporate leadership roles. She served as Chairman, President and Chief Executive Officer of Dun & Bradstreet, Inc. until 2013, having spent 12 years at the company. Prior to this, Sara worked for 18 years at Procter & Gamble where she held a variety of global finance and management positions including Vice President, Finance, Australia, Asia and India. She is also a former Non-Executive Director of Avon Products, Inc. Sara received her MBA from Xavier University, her Accounting degree from the Institute of Cost & Works Accountants and her Bachelor’s degree in Physics, Mathematics and Chemistry from the University of Madras. Key appointments are Campbell Soup Company (Non-Executive Director) and Freddie Mac (Non-Executive Director).

Albert Stroucken

Mr. Albert P. L. Stroucken is Non-Executive Director of the company. He brings to the Board his manufacturing, commercial and international experience. He served as Executive Chairman of Owens-Illinois, Inc. until 2016, having served as Chairman, President and Chief Executive Officer from 2006 until 2015. From 1998 to 2006 Al held the position of President and Chief Executive Officer of H.B. Fuller Company, adding the role of Chairman in 1999. He served as General Manager of the Inorganics division of Bayer AG from 1997 to 1998, serving as Executive Vice President and President of the Industrial Chemicals division of Bayer Corporation from 1992 to 1997. Al served as a Non-Executive Director of Baxalta Incorporated until 2016. Key appointments are Baxter International, Inc. (Non-Executive Director).

Dominic Blakemore

Mr. Dominic Blakemore serves as Non-Executive Independent Director of Shire Plc. Since 1 January 2014. Dominic brings to the Board his strategic and financial experience. He holds the position of Executive Director and Group Chief Operating Officer, Europe at Compass Group PLC, having previously served as Chief Financial Officer. He has also held the positions of Chief Financial Officer at Iglo Foods Group and European Finance & Strategy Director, Corporate Finance Director, and Group Financial Controller at Cadbury plc. Earlier in his career Dominic worked at PricewaterhouseCoopers where he advised pharmaceutical sector clients. Key appointments: Compass Group PLC (Group Chief Operating Officer, Europe) and Academic Council of University College London (Member).

William Burns

Mr. William Burns is bno longer Senior Non-Executive Independent Director of Shire Plc., effective 28 April 2016. He brings to the Board extensive international R&D, commercial, business development and operational experience in the pharmaceutical sector. He worked for Roche from 1986 until 2009; most recently holding the position of CEO of its pharmaceuticals division and serving as a member of the Roche Group Corporate Executive Committee. Bill is a former Non- Executive Director of Roche Holding AG and Chugai Pharmaceutical Co, Ltd, and former Chairman of Biotie Therapies Corp. Bill holds a BA (Hons) in Business Economics from the University of Strathclyde. Key appointments: Masters Pharmaceuticals (Chairman), Biotie Therapies Corp. (Chairman), Mesoblast Limited (Non-Executive Director), Vestergaard Frandsen (Vice Chairman), Wellcome Trust (Committee Chairman), Institute of Cancer Research (Trustee) and University of Cologne/Bonn Center for Integrated Oncology (Scientific Advisory Board Member).

Steven Gillis

Dr. Steven H. Gillis, Ph.D. is Non-Executive Independent Director of Shire plc., since October 1, 2012. Steven brings to the Board his extensive technical and scientific knowledge and commercial experience. He is currently a Managing Director at ARCH Venture Partners; a provider of venture capital for technology firms. Prior to this Steven was a founder and Director of Corixa Corporation, acquired by GlaxoSmithKline in 2005, and before that a founder and Director of Immunex Corporation. An immunologist by training Steven has authored more than 300 peer-reviewed publications in the areas of molecular and tumor immunology. He is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products including Leukine, (GM-CSF), Prokine (IL-2) and Enbrel (soluble TNF receptor-Fc fusion protein) as well as the regulatory approval of Bexxar (radiolabeled anti-CD20) and the novel vaccine adjuvant, MPL. Steven received his BA from Williams College and his PhD from Dartmouth College. Key appointments are ARCH Venture Partners (Managing Director), Pulmatrix, Inc. (Non- Executive Director), PhaseRx Inc. (Chairman and Non-Executive Director) and VBI Vaccines Inc. (Chairman and Non-Executive Director).

David Ginsburg

Dr. David Ginsburg, M.D., is no longer Non-Executive Independent Director of the Company. David brings to the Board his clinical medical experience in internal medicine, hematology-oncology and medical genetics, as well as his extensive basic biomedical laboratory research expertise. David obtained his BA at Yale University, MD at Duke University and completed his medical and research training at Harvard Medical School. David is the recipient of numerous honors and awards, including election to membership at the National Academy of Sciences, the National Academy of Medicine and the American Academy of Arts and Sciences. Key appointments are University of Michigan (James V. Neel Distinguished University Professor of Internal Medicine, Human Genetics and Pediatrics) and Howard Hughes Medical Institute (Investigator).

Anne Minto

Ms. Anne Elizabeth Minto OBE, is no longer Non-Executive Independent Director of Shire Plc., since June 16, 2010. Anne brings to the Board her extensive legal, commercial and remuneration experience. She held the position of Group Director, Human Resources at Centrica plc from 2002 to 2011 and was a member of the Centrica Executive Committee. Her extensive business career includes senior management roles at Shell UK, the position of Deputy Director-General of the Engineering Employers’ Federation and the position of Group Director Human Resources at Smiths Group plc. She is also a former Director of Northumbrian Water plc and SITA UK. Anne holds a Law degree, a postgraduate diploma in Human Resources and is a qualified lawyer. She is also a Fellow of the Chartered Institute of Personnel & Development, the Royal Society of Arts and the London City and Guilds, and is a member of the Law Society of Scotland. Key appointments are Tate & Lyle PLC (Non- Executive Director), ExlService Holdings, Inc. (Non-Executive Director), University of Aberdeen Court (Non-Executive Director) and University of Aberdeen Development Trust (Vice Chairman and Trustee).

Ian Karp